Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring — A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application

详细信息    查看全文

• 作者：Mariusz Tomaniak ; ^{mariusz.tomaniak@interia.pl} ; Aleksandra Gąsecka ; Krzysztof J. Filipiak
• 关键词：MV ; microvesicles ; CVD ; cardiovascular diseases ; SCAD ; stable coronary artery disease ; ACS ; acute coronary syndromes ; EV ; extracellular vesicles ; CD ; clusters of differentiation ; PMV ; platelet-derived MV ; EMV ; endothelial cell-derived MV ; MMV ; monocyte- derived MV ; EryMV ; erythrocyte-derived MV ; NMV ; neutrofile-derived MV ; GP ; glycoprotein ; GPIIb/IIIa ; glycoprotein IIb/IIIa receptor ; GP IX ; glycoprotein IX ; GP Ib ; glycoprotein Ib ; GP IIIa ; glikoprotein IIIa ; HPR ; high-on treatment platelet react
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：226
• 期：Complete
• 页码：93-102
• 全文大小：679 K
• 卷排序：226

文摘

Heterogeneity of microvesicle studies hindered their application in cardiology. Great progresses were made recently in microvesicles' assessment techniques. Multicentre studies with microvesicle analysis are now possible. Microvesicles might become supplementary biomarker in cardiology. Microvesicles may help individualize antiplatelet pharmacotherapy.